Skip to main content
Premium Trial:

Request an Annual Quote

Gene Bridges Inks Genetic-Engineering Alliance With BASF

NEW YORK (GenomeWeb News) — Gene Bridges will use its recombination technology in collaboration with BASF in a genetic-engineering project using E. coli, Gene Bridges said Wednesday.
 
Under the agreement, Heidelberg, Germany-based Gene Bridges will use its Red/ET technology in bio-molecular engineering tasks, and BASF will perform screening and product and process development projects.
 
Gene Bridges said the agreement could “result in a significant acceleration” of development of particular E. coli strains.
 
Gene Bridges offers services, commercial licenses and kits using its recombineering technology.
 
The company’s Red/ET is an in vivo process that involved endogenous proofreading and repair mechanisms of bacterium cells, and is used in genetic engineering. It allows base specific insertion or excision of DNA fragments at selected points on the E. coli genome.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.